Myogenic regulatory factors (MRFs) are known to have essential roles in both the establishment and differentiation of the skeletal muscle cell lineage. MyoD is expressed early in the Xenopus mesoderm where it is present and active several hours before the activation of muscle differentiation genes. Previous studies in cultured cells and in Xenopus laevis have identified sets of genes that require MyoD prior to differentiation of skeletal muscle. Here we report results from experiments using CRISPR/Cas9 to target the MyoD gene in the diploid frog Xenopus tropicalis, that are analysed by RNA-seq at gastrula stages. We further investigate our data using cluster analysis to compare developmental expression profiles with that of MyoD and α-cardiac actin, reference genes for skeletal muscle determination and differentiation. Our findings provide an assessment of using founder (F0) Xenopus embryos from CRISPR/Cas9 protocols for transcriptomic analyses and we conclude that although targeted F0 embryos are genetically mosaic for MyoD, there is significant disruption in the expression of a specific set of genes. We discuss candidate target genes in context of their role in the sub-programs of MyoD regulated transcription.
Introduction
The MyoD family of bHLH transcription factors is well studied developmental regulators that provide a paradigm for how cell lineages are determined during embryogenesis (Tapscott, 2005) . The expression of these key transcriptional regulators is activated in specific cells in the developing embryo by local signals (Emerson, 1993) , and effectors downstream of signal transduction pathways act on discrete enhancers present in MRF genes (Carvajal and Rigby, 2010) . The activation of any one these master regulators is sufficient to drive skeletal muscle differentiation in many types of cultured cells (Tapscott et al., 1988; Weintraub et al., 1989) and this dominant activity is part due to the ability of these transcription factors to auto-and cross-activate each other's expression Weintraub et al., 1989) .
During myogenesis, proliferative myoblasts exit the cell cycle and fuse to form multinucleated myotubes; at the same time the transcription of contractile protein genes is co-ordinately activated. MyoD and Myf5 have overlapping roles that are required for the early commitment of cells to the myogenic lineage, while MRF4 and Myogenin play later roles in myoblast fusion and differentiation (Kaul et al., 2000) . Using cell culture based models of myogenesis, together with chromatin immunoprecipitation and transcriptomics, several sub-programmes of gene expression downstream of MyoD have been described and the transcriptional activity of MyoD in myoblasts prior to the activation of contractile protein genes during differentiation has been established (Bergstrom et al., 2002; Cao et al., 2010; Gianakopoulos et al., 2011; Soleimani et al., 2013) . The outcome of these studies has been a detailed understanding of how the MyoD transcription factor targets genes for transcription, including its surprising widespread binding throughout the genome, preference for a specific E-box sequence, ability to modify chromatin and interact with other transcriptional regulators (Blum et al., 2012; Conerly et al., 2016; Fong et al., 2015) .
In vivo, skeletal muscle cells are derived from the mesoderm and in amniotes the MRFs are first expressed in cells of the early somite . However, in frogs and fish the MRFs are expressed in the mesoderm prior to somitogenesis where MyoD and Myf5 genes are transcribed during gastrula stages (Hopwood et al., 1989; Weinberg et al., 1996) and in Xenopus, the MyoD protein has been localised to the nascent mesoderm by immunohistochemistry (Hopwood et al., 1992) . Xenopus laevis MyoD has been shown to be required for the early expression of a set of genes during gastrulation, prior to any activation of contractile gene expression (Maguire et al., 2012) . This study took advantage of the time window during Xenopus development where the embryo expresses MyoD protein, but myogenic differentiation has not yet begun. Isolating a similar timepoint in amniote embryos would be difficult due to the relatively few myoblasts in the early somite expressing MyoD/Myf5, and the rapid rostral to caudal progression of myogenic differentiation. Therefore, the frog embryo provides a vertebrate model to investigate the requirement for MyoD transcriptional activity prior to myogenic differentiation in vivo.
CRISPR/Cas9 protocols are particularly effective in Xenopus (Liu et al., 2016; Shigeta et al., 2016) : synthetic guide RNAs (gRNAs) are transcribed in vitro and co-injected with Cas9 protein directly into to the one-cell embryo, circumnavigating any delays from transcription and translation inherent to plasmid based protocols used in other systems. Here we used CRISPR/Cas9 to target the MyoD gene in the diploid frog Xenopus tropicalis and analysed gene expression at gastrula stages by RNAseq. We show that founder embryos targeted for MyoD, while genetically mosaic, show specific disruption in the expression of genes previously identified as MyoD targets. We further classify sets of genes identified in our RNAseq analysis according to their expression profile during normal development. This study provides an insight into the earliest genetic targets of MyoD in vivo, as well as an assessment of founder embryos derived from genetic targeting using CRISPR/Cas9 protocols and their usefulness in transcriptomic analyses.
Results
2.1. Gene targeting X. tropicalis MyoD using CRISPR/Cas9 2.1.1. Detecting genetic disruption of MyoD in embryos Xenopus tropicalis is a diploid frog and, as such, genetic methods are simplified using this model. We targeted X. tropicalis MyoD (Fisher et al., 2003) using CRISPR/Cas9 in order to identify genes that require MyoD for their expression in the early mesoderm, prior to myogenic differentiation. A synthetic guide RNA (gRNA) was designed against a sequence in exon 1 coding for the amino terminal part of the bHLH domain, and injected this together with Cas9 protein directly into 1-to 4-cell embryos. In order to test mutagenesis, single embryos were collected for sequencing analysis. Non-homologous end-joining (NHEJ) that repairs DNA after cleavage by Cas9 results in random insertions or deletions (INDELs), therefore genomic DNA was extracted from each embryo and the targeted region of the MyoD gene was amplified by PCR and cloned such that different individual mutations could be identified. A total of 35 embryos were collected and between 3 and 15 clones were sequenced from each individual. Of these 35 embryos, 31 contained at least one mutated sequence (targeting of 88.6%; Fig. 1A ), indicating a high efficiency of gene targeting. As expected, each embryo differed in the proportion of mutant sequences, some returning all mutated sequences, and others showing only 50% mutant sequences.
Characterising alleles
A detailed analysis of the nature of mutations produced by Cas9 targeting, each sequence mutation was characterised to determine whether it was an insertion, a deletion or a point mutation. The average targeting efficiency throughout sequenced embryos shows that 78% of returned sequences were mutated (Fig. 1B) , of which the majority were deletions (77%) rather than insertions or point mutations (Fig.  1C ). We found that the level of mosaicism within a single embryo was high, and Fig. 1D shows 10 sequences from a single embryo aligned to the predicted wild type MyoD sequence. As predicted, all mutation events occur and the near the protospacer-adjacent motif (PAM) where NHEJ results in many different alleles (Shigeta et al., 2016) . Fig.  1E depicts the proportion of the alleles that code for frameshift mutations as a result of either a deletion or an insertion. We found that only a small proportion of sequences (2.3%) represent in-frame insertions. Frameshift mutations represent the majority of mutated sequences identified, however, this equates to less than half of all sequences returned (43.7%). This highlights a caveat when using F0 embryos for genetic analyses; although CRISPR/Cas9 targeting results in a very high proportion of mutated alleles in an individual embryo, in this case, less than half of these mutations will result in a truncated protein or a genetic null. To further characterise embryos targeted by CRISPR/Cas9, we extracted mRNA from groups of ten embryos at NF stage 11.5 and used qPCR to analyse the expression of MyoD and its known target gene Rbm24 (Seb4) (Li et al., 2010) . We found that there is a significant decrease in Myod expression (P b 0.01) and Rbm24 (P b 0.05) when embryos injected with MyoD gRNA + Cas9 protein are compared to those injected with embryos injected with the same amount of Cas9 protein alone. The results were calculated as relative proportions of expression and repeated for three biological replicates; we found that the relative expression of Myod in targeted embryos compared with controls is reduced to 0.57 and Rbm24 is reduced to 0.77 ( Fig. 2A) .
Identifying genes that require MyoD using RNA-seq analysis
Three biological repeats for X. tropicalis experimental embryos (targeted for MyoD) and sibling controls (Cas9-only injected) were collected at NF stage 11.5 and mRNA was extracted for RNA-seq. cDNA libraries were prepared and Illumina deep sequencing resulted in 440 million reads across the 6 samples. RNA-Seq reads were mapped using the Xenopus tropicalis genome version 9.0 (Xenbase.org) and FPKM values were established for all genes. Transcripts that align to MyoD were analysed for INDELs, and Fig. 2B shows that a significant proportion of the reads have deletions in the expected target site adjacent to the PAM. Insertions are less likely to be detected as they would fail to align with reference genome.
To produce an overview of the significance of fold changes observed in CRISPR targeted samples, a volcano plot for (log 2 ) fold change vs (− log 10 ) paired t-test P-value was constructed using Python script (Fig. 3) . Each individual point represents a gene and the dotted line represents a P-value of b 0.05. Points in red indicate genes with a fold change of b 1; that is, where the average FPKM value of experimental samples have not doubled or halved compared to that of the control. Blue points represent genes with a fold change N1 but a P-value of N0.05, so not statistically significant. Yellow points represent genes with a fold change N 1 and a P-value of b0.05. The majority of points show a fold change of b1 and P-values of N0.05, indicating no significant change in gene expression at NF stage 11.5 in response to CRISPR/Cas9 targeting of MyoD. However, 1165 genes mapped to the X. tropicalis genome display significant change and are further analysed in Sections 2.3.
Computational analysis of early genetic targets of MyoD
Of the 1165 genes found to be significantly altered in the absence of MyoD, some showed very low expression levels. Therefore, a minimum expression threshold of 5.0 FPKM average for the control samples was applied. In addition, as MyoD expression in targeted samples showed a fold change of 0.71, therefore genes with fold changes in this same range (between 0.68 and 0.91) were selected for further analysis. During our manual curation, we included two genes that fell just outside the criteria cutoff: FoxC1 (0.84; P b 0.058) and Pbx2 (0.93; P b 0.02). This resulted in a short list of 100 potential target genes (Supplemental data, Table S1 ).
Temporal expression analysis of potential target genes
To further investigate whether the identified genes are expressed at a time consistent with activation by MyoD, temporal expression profiles were analysed. As MyoD protein is first detected in the mesoderm at NF stage 11, candidate genes with expression prior to these stages are less likely to be bonafide target genes of MyoD. Furthermore, as our analysis was carried out at Stage 11.5, genes coding for contractile proteins or other differentiation specific genes are not expected to be identified by our study, however, we include the expression profile of actc1 as a reference for this class of genes. RNA-Seq data from a development Sequences were aligned to the predicted wild type amplicon sequence (bottom row) and the Cas9 PAM sequence is indicated in red underline. (E) Individual sequences were assessed for deletions, insertions and missense mutations. Mutations causing INDELs in multiples of 3 were categorised as in-frame deletions/insertions. 25.9% sequences returned were confirmed wild type, 35.1% showed frame shift deletions, 8.6% showed frame shift insertions, 24.1% showed in frame deletions, 2.3% showed in frame insertions and 4% showed missense mutations. (Blue indicates mutation or disruption; orange indicates wildtype sequence or silent mutation).
time course of Xenopus tropicalis is available (Tan et al., 2013) and these expression profiles were used for hierarchical cluster analysis of target genes. To do this, expression data was extracted for the 100 short-listed genes (Supplemental data Table S1 ) and used to create a heatmap of expression levels over a developmental time course (Supplemental data Fig. S1 ). Genes aligning with reference profiles for determination (myod1) and differentiation (actc1) were selected for further heat mapping and cluster analyses (shown in Figs. 4 and 5). Euclidean distance was used as the metric of linkage for complete samples and a selected cutting point for the clustered dendrogram resulted in the formation of 5 clusters of distinct expression profiles; this is shown in the heat map where orange boxes represent highest expression levels (Fig. 4) . To determine the expression patterns observed within the 5 clusters, profiles of relative expression for each stage were constructed from the expression data used in the heatmap and clustering.
Clusters 1 and 2 show similar overall expression profiles: genes within these clusters have very low or no maternal expression with earliest notable expression at stage 10. Expression in both clusters increases during gastrula and neurula stages, however, in Cluster 1 expression increase is more rapid, as highest expression is observed at stages 13-14, while genes in Cluster 2 show peak expression at stages 16-18. Both clusters then show decreases in gene expression in later stages. Notably, MyoD itself is allocated to Cluster 2. Genes located in Cluster 3 also show low or no expression prior to mid-blastula transition (MBT) and the overall expression trend shows increasing expression until early tailbud stages 20-22. Expression then decreases in later stages. Individual gene expression within this cluster however, is more varied than in other clusters. Cluster 4 is a much smaller cluster containing the known MyoD target alpha-cardiac actin (actc1). Gene expression for this cluster shows delayed gene activation with increases occurring from stage 14 onwards, this increasing expression is maintained through tailbud stages and only decreases slightly in the later tadpole stages. Cluster 4 contains the muscle glycogen phosphorylase pygm. Cluster 5 is distinct from all other clusters in that the genes located within this cluster show maternal expression. Expression decreases rapidly after MBT and is at lowest levels during neurula stages, then increases again during tailbud stages (20-28) through to later tadpole stages (31-45).
Hierarchical cluster analysis was used to highlight genes that show developmentally relevant expression profiles, and strengthen their status as candidates for early genetic targets of MyoD; clusters 1 and 2 include genes identified in other studies as myogenic or pre-myogenic genes (highlighted by an asterisk and discussed in Section 3). In order to validate whether any of these genes require MyoD for their expression during gastrula stages, we injected gRNA targeting MyoD together with Cas9 protein and directly assayed the expression of several candidate genes in these embryos at stage 11.5 as compared to Cas9 only injected embryos using qPCR (Fig. 5) . Fig. 5 shows that Rbm20, Rbm24, gli2, FoxC1, and Zeb2 (aka XSip1), as well as myoD itself, are all significantly down-regulated in targeted embryos. This validation supports the notion that our gene targeting and transcriptomic analysis of founder embryos has provided a robust list of candidates genes regulated by MyoD prior to the onset of skeletal muscle differentiation.
Discussion
MyoD is known to direct several different sub-programmes of gene expression during myogenesis (Bergstrom et al., 2002; Blais et al., 2005; Soleimani et al., 2012 ) consistent with its role as an essential determination gene for the proliferative myoblast (Rudnicki et al., 1993) . However, MyoD is also a robust initiator of transcriptional targets during myogenic differentiation, distinguishing itself in this way from Myf5 (Conerly et al., 2016) . It is an interesting proposition that one transcription factor can activate distinct panels of genes at two different Fig. 4 . Hierarchical clustering of Myod target genes. Genes identified as significantly downregulated in targeted samples were further analysed using expression data from (Tan et al., 2013) to create a heatmap. Relative expression is shown as a scale of low (blue) to high (orange). Euclidean distance was used as the metric for hierarchical clustering of complete samples, which resulted in 5 clusters showing distinct expression profiles. (*) indicates genes which have known or predicted roles in myogenic or pre-myogenic cells. Myod and a-actin (actc1) were included in the analysis to highlight relevant clusters. stages of cell lineage specification. Indeed, this notion of promoter swapping is supported by MyoD binding analysis using chromatin immunoprecipitation (ChIP-seq) protocols that have shown that MyoD functions as a transcriptional regulator during both myogenic determination and differentiation by binding and activating distinct sets of genes (Soleimani et al., 2012) . The ability to model myogenic differentiation in cell culture has been exceptionally informative; pointing the way to a detailed understanding of how transcriptional regulators can direct cell fate. Our study investigated genes that require MyoD during the earliest stages of myogenesis in vivo, using the diploid frog model X. tropicalis. CRISPR/Cas9 gene editing very effectively targeted the MyoD gene in embryos, however not all INDELs result in alleles that would generate a disrupted protein. Approximately 80% of injected embryos are successfully targeted and the penetrance of mutation in each individual is also very high. However, because Cas9 can act on one or both (or neither) alleles in cells as the early embryo divides, and the nature of NHEJ is leads to random INDELs, the resulting F0 embryos are inherently genetically mosaic. This leads to a population of F0 s with ill-defined genotype, with less than half of alleles analyses carrying a disruptive mutation. In zebrafish, it is standard practice to outcross founder fish and breed to a known mutant genotype (Li et al., 2016) ; outcrossing frogs is not as practical as it requires more space and time.
Nevertheless, we have established here that using founder embryos from gene editing protocols in transcriptional analyses is valuable. We show here that CRISPR/Cas9 targeting of MyoD results in a significant reduction of MyoD transcripts overall and a high percentage of these with INDELs (Fig. 2) ; moreover, the known target gene Rmb24 (Seb4) is significantly down regulated in these samples. Our transcriptomic analysis has provided a shortlist of genes that require MyoD, in vivo, prior to myogenic differentiation (Table 1) .
Our analysis of putative MyoD targets in the context of a published time course of gene expression during Xenopus tropicalis development (Tan et al., 2013 ) provided a way of curating genes on the basis of temporal expression, however spatial restriction of expression is also an important factor to consider. MyoD and Rbm24 (aka Seb4) share a very close expression pattern, both temporally and spatially, with the notable exception that Rbm24 is expressed in the cardiac as well as the skeletal muscle cell lineage (Li et al., 2010; Maguire et al., 2012) . The spatial expression pattern of Rbm20 has not been examined in Xenopus, however, in chick embryos it shows very early (yet transient) expression in somites with persistent expression the heart (Geisha.arizona.edu). Gli2 and Zeb2 (aka XSip1) are expressed in the neurectoderm just after gastrulation (Aguero et al., 2012; Papin et al., 2002) . The mesoderm, where MyoD is active as a transcriptional regulator, provides signals that instruct the overlying ectoderm to become neural tissue, so it is possible that there is an indirect regulation of these genes. This reflects one limitation of this type of study where the genes identified are not necessarily direct targets; however, there is evidence that at least some of them are. FoxC1 shows both early mesodermal and later somitic expression in Xenopus, and like Rbm24, FoxC1 was also identified as a direct target of MyoD in a previous analysis using morpholino oligos (Maguire et al., 2012) . Moreover, during gastrulation Zeb2 is expressed in the dorsal marginal zone with some more lateral mesodermal expression overlapping with MyoD, and there is no in situ hybridization data for gastrula specific expression of Gli2.
FoxC1 and FoxC2 are significant targets in our analyses and are known to be expressed in the paraxial mesoderm amniotes (Kume et al., 1998) , as well as fish and frogs (Köster et al., 1998; Maguire et al., 2012; Topczewska et al., 2001 ). FoxC1/C2 are essential for somitogenesis Topczewska et al., 2001) , and identified as transcriptional targets of MyoD in previous studies Table 1 A shortlist of genes identified as early genetic targets of MyoD. After heat-mapping and cluster analysis, only genes located within clusters showing developmentally relevant expression profiles were shortlisted as early MyoD targets. The list was manually curated using existing available expression profiles and published literature to curate the 33 genes shortlisted as early targets of MyoD. (Gianakopoulos et al., 2011; Maguire et al., 2012) . In the early paraxial mesoderm, FoxC1/C2 are co-expressed with the early muscle regulator Pax3, however later in somitogenesis FoxC1/2 regulate the endothelial lineage (Lagha et al., 2009; Mayeuf-Louchart et al., 2014) but their expression is nonetheless essential for the normal migration of muscle precursor cells to the limb (Mayeuf-Louchart et al., 2016) . Interestingly, another gene we identified in our screen, Gli2, has been found to act upstream of FoxC1/2 in the induction of myogenesis in P19 cells (Savage et al., 2010) . Pbx2 is also an interesting target as this family of TALE-class homeodomain proteins are associated with myogenesis (Berkes et al., 2004; Maves et al., 2007) and binding sites for Pbx transcription factors are found in regions of the genome associated with MyoD binding (Fong et al., 2015) ; it is thought that Pbx proteins help 'pioneer' or establish the myogenic programme (Yao et al., 2013) . This model fits well with Pbx genes being early targets of MyoD in vivo. Rbm24 (Seb4) is an RNA binding protein essential for skeletal muscle specific alternative splicing (Yang et al., 2014) and has been shown previously to be a direct target of MyoD (Li et al., 2010) . Recently, it has been found that Rbm24 is essential for normal somitogenesis in fish (Maragh et al., 2014) consistent with the findings in our previous publication in Xenopus where Rbm24 was identified as a MyoD target gene (Maguire et al., 2012) . Rbm20, a related gene with similar functions in directing cell specific alternative splicing , was also identified as a target in our analyses. Zeb2 codes for an E-box binding repressor, which could act like Snail repressors in modulating 'enhancer swapping', where MyoD binds to regulatory sequences in different genes in myoblasts as compared with myotubes (Soleimani et al., 2013) . Genes coding for the zinc finger transcription factors Sp8 and Sp5 were also identified as targets in a screen for early targets of Wnt signalling (Nakamura et al., 2016) and as downstream regulators promoting FGF signalling (Branney et al., 2009; Kasberg et al., 2013) . Identifying the genes coding for Sp5/8 as early MyoD targets is consistent with the important role for FGF (Fisher et al., 2002) and Wnt (Hoppler et al., 1996) signalling in activating MyoD in Xenopus. The fact that we find some regulators that are known to act with MyoD (such as Pbx and Sp5/8) as downstream targets of MyoD is not surprising as our analyses focus on a window of time very early during the specification of the myogenic lineage when transcriptional feed-forward pathways are being established. More surprising is that we were able to detect later targets of MyoD at this early stage: the skeletal muscle specific protocadherins (pcdh8) and kinases (pgk1 and pygm), and follistatin (fstl1) are expressed in somites (Berti et al., 2015) and are notable as they are identified as MyoD targets at such an early timepoint.
Considering the statistically significant hits identified in our study in the context of their normal developmental expression patterns and with regard to other findings in the published literature, we describe here a set of genes ( Table 1) The basic domain of MRFs functions as a DNA binding domain, binding at E-box consensus sequences in regulatory regions downstream genes to activate transcription. Therefore, a synthetic guide RNA sequence (gRNA) was designed to disrupt a region within the Xenopus tropicalis MyoD basic domain, located in exon 1 of the coding sequence. The design tool ChopChop (https://chopchop.rc.fas.harvard.edu/) was used to scan the input sequence for suitable Cas9 target sequences including a PAM site. Any off-targets with up to 2 mismatches in the first 20 bp of sequence were searched for using the Xenopus tropicalis genome version (xenTro3/GCA_000004195.1).
gRNA template synthesis
A sequence spanning 71-89 bp in the first exon of the XtMyoD coding sequence.
(5′-TCGTCGTAGAAGTCATCGG-3′) on the reverse strand was selected as no off-targets were predicted for this sequence. We designed the 5′ primer to include an increased efficiency promoter for transcription by T7 RNA Polymerase, and an added 5′ G nucleotide to fit requirements of the T7 polymerase. Our resulting forward primer consisted of the sequence.
5′-GCAGCTAATACGACTCACTATAGG TCGTCGTAGAAGTCATCGG GTTTTAGAGCTAGAAATA-3′ and the reverse primer is common to all gRNAs is 5′AAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGAC TAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAAC 3′ (Nakayama et al., 2014) .
gRNA transcription
Phusion polymerase was used to amplify the template using 5 μM of each primer, annealing at 60°C and extending for 15 s over 35 cycles. Template was taken directly from the PCR reaction for in vitro transcription using Megashortscript® T7 Transcription Kit (Life Technologies) following the manufacturers guidelines. Incubation at 37°C overnight was followed by TURBO DNase treatment, and gRNA purification by phenol-chloroform extraction and NH 4 OAc/ethanol precipitation. gRNA was resuspended in a final volume of 20 μl. RNA quality assessment by gel electrophoresis and nanodrop measurement was also carried out. An optimal concentration of 1.8μg/μl is desired for Cas9 coinjection mixtures.
Cas9 protein production
Cas9 protein was made using the plasmid (Addgene) by expressing in Rosetta-2 cells (Novagen) at 30 C in kanamycin/chloramphenicol substituted autoinduction media (Studier F.W., Protein Expression and Purification 2005). Pelletted cells were resuspended in lysis buffer (buffer A (50 mM Tris-HCl pH 8.0, 500 mM NaCl, 10 mM imidazole) with cOmplete EDTA-free protease inhibitor cocktail (Roche) and lysed by sonication. GE Healthcare HiTrap Nickel NTA column was equilibrated in 50 mM Tris-HCl pH 8.0, 500 mM NaCl, 10 mM imidazole) and washed before a gradient of Buffer B (Buffer A + 500 mM Imidazole) was applied to elute the protein. The peak eluted between 7 and 30% buffer B. The fractions containing Cas9 were pooled and concentrated before size-exclusion chromatography in 20 mM Tris, 200 mM KCl, 10 mM MgCl 2 (Superdex 200 16/60; Amersham Pharmacia Biotech). The purified Cas9 was concentrated to 50 mg/ml using ultrafiltration in Amicon centrifugation filter units (Millipore). Aliqouts were flashfrozen and stored at −80°C.
Analysis of X. tropicalis embryos 4.2.1. Genotyping embryos
To assess the efficiency of Cas9 targeting, genomic DNA was extracted from single embryos and the target region was amplified by PCR, cloned into pGEM T-easy and sequenced. Single embryos at NF Stage 25 were transferred to 0.5 ml PCR tubes containing 200ul of lysis buffer (50 mM Tris pH 7.0, 50 mM NaCl, 5 mM EDTA, 0.5% SDS, 10% Chelex, fresh 250μg/ml Proteinase K) and incubated at 55°C for 1 h followed by 95°C for 15 min to deactivate the Proteinase K. After centrifugation, the DNA is diluted 1:10 and amplified by PCR reaction using primers flanking the Cas9 target site (forward: TTA CTT TGC GCC GTT GCT AT and reverse: GTT GCG CAA AAT CTC CAC TT). PCR products were cloned into the pGEM®-T Easy vector system as per manufacturer's guidelines and transformed into E. coli. Minipreps of individual clones sequenced by GATC Biotech using an SP6 primer.
Sequences from 3 to 10 clones from each embryo were aligned alongside the wild type amplicon sequence using DNAStar SeqMan to identify INDELs.
Expression analysis of targeted embryos
To assess the level of MyoD transcripts and that of its known target Rmb24 (Seb4) in CRISPR/Cas9 targeted embryos prior to RNA-Seq analysis, control and experimental embryos were collected at NF stage 11.5 and snap frozen on dry ice. RNA was extracted using Sigma TRI Reagent® together with Zymo RNA Clean & Concentrator™-5 column, and purified as per the manufacturer's instructions. For qPCR, cDNA was synthesised using Thermo Fisher Scientific Superscript IV Reverse Transcriptase according to manufactures guidelines. Primers for MyoD, Rmb24, and normalisation gene Dicer were used with Fast SYBR Green 2 × master mix in triplicate for three biological repeats. For validation of identified target genes, additional primers for Rbm20, Foxc1, Gli2 and Zeb2 were designed and an additional PCR analysis for three biological replicates was carried out.
RNAseq
RNA was extracted as described above from 10 embryos at NF stage 11.5; controls were injected only with 1 ng Cas9 protein and experimental embryos with 1 ng Cas9 protein together with 300 pg gRNA designed against MyoD. mRNA libraries were prepared for sequencing using the NEBNext® Ultra™ RNA Library Prep Kit for Illumina, using the NEBNext Poly(A) mRNA Magnetic Isolation Module to isolate poly(A) mRNA from total RNA. HiSeq3000 2 × 150 bp paired end sequencing was performed by the University of Leeds Next Generation Sequencing Facility.
Computational analysis of RNAseq data
Illumina deep sequencing resulted in~440million reads across the 6 samples. Raw RNA-Seq reads were mapped using the Xenopus tropicalis genome version 9.0 (Xenbase). FPKM (fragments per kilobase of transcript per million mapped reads) values were calculated to normalise the number of reads per fragment to the length of the fragment in order to avoid bias towards longer fragments. FPKM values for three biological replicates were analysed by pairwise t-tests comparing expression in control and MyoD CRISPR-targeted samples. 655 genes showed differential expression based on paired t-tests (P b 0.05). Expression data for target genes was extracted from RNA-seq data available (Tan et al., 2013) and uploaded to https://software.broadinstitute.org/ morpheus/ creating a heatmap of expression and hierarchical clustering.
